Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Parkinson's disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: a 3-year European multicenter study with repeat [123I]FP-CIT SPECT.
Marshall VL, Reininger CB, Marquardt M, Patterson J, Hadley DM, Oertel WH, Benamer HT, Kemp P, Burn D, Tolosa E, Kulisevsky J, Cunha L, Costa D, Booij J, Tatsch K, Chaudhuri KR, Ulm G, Pogarell O, Höffken H, Gerstner A, Grosset DG. Marshall VL, et al. Among authors: reininger cb. Mov Disord. 2009 Mar 15;24(4):500-8. doi: 10.1002/mds.22108. Mov Disord. 2009. PMID: 19117369 Clinical Trial.
Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study.
McKeith I, O'Brien J, Walker Z, Tatsch K, Booij J, Darcourt J, Padovani A, Giubbini R, Bonuccelli U, Volterrani D, Holmes C, Kemp P, Tabet N, Meyer I, Reininger C; DLB Study Group. McKeith I, et al. Lancet Neurol. 2007 Apr;6(4):305-13. doi: 10.1016/S1474-4422(07)70057-1. Lancet Neurol. 2007. PMID: 17362834 Clinical Trial.
Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study.
Barthel H, Gertz HJ, Dresel S, Peters O, Bartenstein P, Buerger K, Hiemeyer F, Wittemer-Rump SM, Seibyl J, Reininger C, Sabri O; Florbetaben Study Group. Barthel H, et al. Lancet Neurol. 2011 May;10(5):424-35. doi: 10.1016/S1474-4422(11)70077-1. Epub 2011 Apr 8. Lancet Neurol. 2011. PMID: 21481640 Clinical Trial.
Aβ imaging with 18F-florbetaben in prodromal Alzheimer's disease: a prospective outcome study.
Ong KT, Villemagne VL, Bahar-Fuchs A, Lamb F, Langdon N, Catafau AM, Stephens AW, Seibyl J, Dinkelborg LM, Reininger CB, Putz B, Rohde B, Masters CL, Rowe CC. Ong KT, et al. Among authors: reininger cb. J Neurol Neurosurg Psychiatry. 2015 Apr;86(4):431-6. doi: 10.1136/jnnp-2014-308094. Epub 2014 Jun 26. J Neurol Neurosurg Psychiatry. 2015. PMID: 24970906 Clinical Trial.
Individualized quantification of brain β-amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer's disease and healthy controls.
Barthel H, Luthardt J, Becker G, Patt M, Hammerstein E, Hartwig K, Eggers B, Sattler B, Schildan A, Hesse S, Meyer PM, Wolf H, Zimmermann T, Reischl J, Rohde B, Gertz HJ, Reininger C, Sabri O. Barthel H, et al. Eur J Nucl Med Mol Imaging. 2011 Sep;38(9):1702-14. doi: 10.1007/s00259-011-1821-1. Epub 2011 May 6. Eur J Nucl Med Mol Imaging. 2011. PMID: 21547601 Clinical Trial.
Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: phase 3 study.
Sabri O, Sabbagh MN, Seibyl J, Barthel H, Akatsu H, Ouchi Y, Senda K, Murayama S, Ishii K, Takao M, Beach TG, Rowe CC, Leverenz JB, Ghetti B, Ironside JW, Catafau AM, Stephens AW, Mueller A, Koglin N, Hoffmann A, Roth K, Reininger C, Schulz-Schaeffer WJ; Florbetaben Phase 3 Study Group. Sabri O, et al. Alzheimers Dement. 2015 Aug;11(8):964-74. doi: 10.1016/j.jalz.2015.02.004. Epub 2015 Mar 28. Alzheimers Dement. 2015. PMID: 25824567 Free article. Clinical Trial.
36 results